百诚医药 (301096)

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.

ASZ

Tags

Contract Research Organization (CXO)Innovative DrugsMedical Aesthetics ConceptPet EconomyHelicobacter PyloriNon-GAAP LossesPlanned Reduction of HoldingsResearch and Experimental DevelopmentBelow IPO PriceMargin Trading and Securities LendingChiNext Small CapChiNext Tech

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 10922.83
  • Circulating A-Shares(W): 8278.72
  • Earnings Per Share(RMB): 0.0600
  • Net Assets Per Share(RMB): 23.6703
  • Operating Revenue(W RMB): 50988.37
  • Total Profit(W RMB): 796.51
  • Net Profit Attributable to Parent(W RMB): 612.42
  • Net Profit Growth Rate(%): -95.68
  • Weighted Return on Equity(%): 0.2400
  • Operating Cash Flow Per Share(RMB): -1.6460
  • Undistributed Profit Per Share(RMB): 3.3416
  • Capital Reserve Per Share(RMB): 19.2882

2. Main Business

The main business covers:

  • Pharmaceutical technology contract research services (CRO business)
  • R&D technology achievement transformation services
  • Customized R&D and production services (CDMO)

3. Company Basic Information

  • Company Name: Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd.
  • Listing Date: 2021-12-20
  • Industry: Research and Experimental Development
  • Address: No. 159, Lvzhou Road, Donghu Street, Linping District, Hangzhou City, Zhejiang Province
  • Website: www.hzbio-s.com
  • Company Profile: The issuer was established as a joint stock company through the overall change of Bai Cheng Limited. On October 13, 2015, Bai Cheng Limited held a shareholders' meeting and passed a resolution, unanimously agreeing to transform Bai Cheng Limited into a joint stock company with the audit and evaluation base date of September 30, 2015. On November 26, 2015, Zhong Shen Asia Pacific Certified Public Accountants (Special General Partnership) issued the "Zhong Shen Asia Pacific Audit Document (2015) 020622" Audit Report, using September 30, 2015 as the audit base date. The audited net assets of Bai Cheng Limited were 11,710,500 yuan, of which the paid-in capital was 5,750,000 yuan, capital reserve was 7,250,000 yuan, and undistributed profit was -1,289,400 yuan. According to the "Evaluation Report" (Tianyuan Ping Bao Zi [2015] No. 0422) issued by Tianyuan Asset Appraisal Co., Ltd., as of September 30, 2015, the evaluated net asset value of Bai Cheng Limited was 12,241,000 yuan. On December 15, 2015, all shareholders of Bai Cheng Limited, as promoters, jointly signed the "Agreement on Jointly Establishing Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd.", stipulating that the audited net asset value of Bai Cheng Limited as of September 30, 2015 would be converted into shares at a ratio of 1.0183067:1, with the shareholders of the limited company converting their shares in proportion, resulting in a total share capital of 11,500,000 shares for the joint stock company, with a par value of 1 yuan per share. The premium portion of the company's audited net assets, amounting to 210,500 yuan, was recorded as capital reserve. On the same day, the promoters held the inaugural meeting and the first shareholders' meeting of the joint stock company. According to the "Capital Verification Report" (Zhong Shen Asia Pacific Yan Zi (2015) 020722) issued by Zhong Shen Asia Pacific Certified Public Accountants (Special General Partnership) on December 22, 2015, as of December 13, 2015, the company had received the share capital of 11,500,000 yuan converted from the audited net assets of Bai Cheng Limited as of the base date of September 30, 2015, with the balance of 210,500 yuan recorded as capital reserve. On December 21, 2015, the Hangzhou Market Supervision Administration approved the establishment of Bai Cheng Pharma-Tech and issued the "Business License" (Unified Social Credit Code: 91330108577318224J).

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Hangzhou Qinghai Management Consulting Partnership (Limited Partnership) General Legal Person 370.00 4.47
2 Hangzhou Yuexiang Enterprise Management Partnership (Limited Partnership) General Legal Person 330.00 3.99
3 Hangzhou Yirui Equity Investment Management Partnership Enterprise (Limited Partnership) General Legal Person 180.00 2.17
4 Huatai Financial Holdings (Hong Kong) Limited - Client Funds General Legal Person 139.30 1.68
5 CITIC Securities Asset Management (Hong Kong) Limited - Client Funds Asset Management Plan 136.18 1.64
6 Fucheng Haifu Asset Management - Hangzhou Bank - Fucheng Haifutong Bai Cheng Pharma-Tech Employee Participation in ChiNext Strategic Placement Collective Asset Management Plan Asset Management Plan 113.07 1.37
7 Huaxia China Securities 2000 Index Enhanced Initiation Securities Investment Fund Class A Fund 0.34 0.00

5. Concept Sectors

  • Medical Aesthetics Concept
  • CXO Concept
  • Helicobacter Pylori
  • Innovative Drugs
  • Pet Economy
  • Margin Trading & Securities Lending
  • Non-Recurring Loss
  • Below IPO Price
  • Intended Reduction
  • ChiNext Technology
  • ChiNext Small Cap

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information